What This Bill Does
The Medication Affordability and Patent Integrity Act would require sponsors of drug and biologic applications to certify that certain patent-related statements they give the FDA match what they tell the Patent and Trademark Office. It would also require them to send patentability-related information to the PTO when they submit it to the FDA, and to include those certifications in new drug and biologic applications filed under section 505 of the Federal Food, Drug, and Cosmetic Act and section 351 of the Public Health Service Act. The bill applies to new applications after enactment and, for older applications, to later-filed patents and later communications. It would also add an FDA enforcement hook and direct the PTO to protect confidential or trade-secret material when it receives information from FDA filings.
- Requires drug sponsors to certify that FDA submissions match what they tell the Patent and Trademark Office.
- For FDA-regulated drugs, the bill applies to applications under section 505 of the FDCA.
- For biologics, it adds parallel disclosure rules under section 351 of the Public Health Service Act.
- Covers information material to patentability, including chemistry, manufacturing, and controls data and prior-art statements.
- Directs the PTO to preserve trade-secret, confidential, and financial information protections for transferred material.
Who This Bill Affects
If enacted, this bill would most directly affect drug and biologic manufacturers, especially companies that file patent applications or make patent-related statements while also seeking FDA approval. For the general public, the practical effect would be indirect: if the disclosures reduce weak or inconsistent patent claims, some medicines could face competition sooner, which may help lower prescription costs over time. Companies would, however, face added filing and compliance steps with both FDA and the PTO.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Patients and consumer advocates They would likely argue the bill could curb gamesmanship around drug patents and make it harder to use inconsistent filings to stretch monopolies. If that helps competition arrive sooner, patients and insurers could benefit from lower drug costs.
- Generic and biosimilar manufacturers They would likely support clearer, more consistent patent disclosures because it can reduce uncertainty around which patents are truly supported by the underlying record. That can make market-entry planning less risky and potentially speed competition.
- Public payers and health-plan sponsors They may see value in better patent transparency if it helps limit litigation over questionable patents and reduces avoidable delays in lower-cost alternatives. Even modest improvements in competition can matter for formularies and public spending.
- Pharmaceutical and biotechnology companies They may argue the bill adds duplicative disclosure burdens and forces companies to coordinate sensitive scientific, regulatory, and patent information across agencies. They may also worry about legal exposure if disclosure mistakes are treated as enforcement violations.
- Patent practitioners and in-house counsel They may object that the new certification and disclosure requirements increase compliance complexity and create new traps for inadvertent inconsistency. The requirement to transmit patentability-related information to PTO may also complicate privileged or confidential review processes.
- Companies with extensive trade-secret manufacturing information Even with confidentiality protections, these firms may worry about expanded information flow between agencies and the possibility of later disputes over what had to be disclosed. They could view that as risky for proprietary chemistry and manufacturing know-how.
Key Implications
-
““certify to the Food and Drug Administration... consistent with the information ... provided to the United States Patent and Trademark Office””
Sponsors would have to align the story they tell regulators and patent examiners. That is meant to reduce contradictions, but it also creates a compliance obligation that could trigger scrutiny if the records diverge.
-
““submit to the United States Patent and Trademark Office any information material to patentability””
The PTO would receive patent-relevant material that overlaps with FDA submissions. In practical terms, this could make it harder to withhold important scientific facts from the patent process while still using them in drug approval filings.
-
““any statement or characterization of analytical data... in the chemistry, manufacturing, and controls section””
The bill specifically targets CMC-related statements, which are central to how a drug is made and tested. Those details can matter both for FDA approval and for whether a patent claim is well supported.
-
““submit to the United States Patent and Trademark Office any information the Food and Drug Administration provided in response””
This is a two-way information flow requirement tied to patentability. It could bring FDA feedback into the patent record, giving patent examiners a fuller picture but also increasing the amount of material companies must track.
-
““shall remain subject to application protections for trade secret or confidential information””
The bill tries to preserve secrecy even while expanding disclosure. That protection matters because many drug-development and manufacturing details are commercially sensitive, and companies are likely to resist any rule that weakens those safeguards.
Latest Status
June 17, 2026
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.